JP2006514015A5 - - Google Patents

Download PDF

Info

Publication number
JP2006514015A5
JP2006514015A5 JP2004555618A JP2004555618A JP2006514015A5 JP 2006514015 A5 JP2006514015 A5 JP 2006514015A5 JP 2004555618 A JP2004555618 A JP 2004555618A JP 2004555618 A JP2004555618 A JP 2004555618A JP 2006514015 A5 JP2006514015 A5 JP 2006514015A5
Authority
JP
Japan
Prior art keywords
substituted
unsubstituted
group
alkyl
nhr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2004555618A
Other languages
English (en)
Japanese (ja)
Other versions
JP4914008B2 (ja
JP2006514015A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2003/037418 external-priority patent/WO2004047826A1/en
Publication of JP2006514015A publication Critical patent/JP2006514015A/ja
Publication of JP2006514015A5 publication Critical patent/JP2006514015A5/ja
Application granted granted Critical
Publication of JP4914008B2 publication Critical patent/JP4914008B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2004555618A 2002-11-21 2003-11-21 免疫寛容を誘導するためのジアミド誘導体と免疫抑制剤との組み合わせ Expired - Fee Related JP4914008B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US42832802P 2002-11-21 2002-11-21
US60/428,328 2002-11-21
PCT/US2003/037418 WO2004047826A1 (en) 2002-11-21 2003-11-21 Combination of diamide derivatives and immunosuppressive agents for induction of immune tolerance

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2010236925A Division JP2011016851A (ja) 2002-11-21 2010-10-21 免疫寛容を誘導するためのジアミド誘導体と免疫抑制剤との組み合わせ

Publications (3)

Publication Number Publication Date
JP2006514015A JP2006514015A (ja) 2006-04-27
JP2006514015A5 true JP2006514015A5 (https=) 2007-01-11
JP4914008B2 JP4914008B2 (ja) 2012-04-11

Family

ID=32393383

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2004555618A Expired - Fee Related JP4914008B2 (ja) 2002-11-21 2003-11-21 免疫寛容を誘導するためのジアミド誘導体と免疫抑制剤との組み合わせ
JP2010236925A Withdrawn JP2011016851A (ja) 2002-11-21 2010-10-21 免疫寛容を誘導するためのジアミド誘導体と免疫抑制剤との組み合わせ

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2010236925A Withdrawn JP2011016851A (ja) 2002-11-21 2010-10-21 免疫寛容を誘導するためのジアミド誘導体と免疫抑制剤との組み合わせ

Country Status (9)

Country Link
US (3) US7217718B2 (https=)
EP (1) EP1562571B1 (https=)
JP (2) JP4914008B2 (https=)
AT (1) ATE520400T1 (https=)
AU (1) AU2003291143A1 (https=)
DK (1) DK1562571T3 (https=)
ES (1) ES2371635T3 (https=)
PT (1) PT1562571E (https=)
WO (1) WO2004047826A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100494182C (zh) 2000-05-12 2009-06-03 基酶有限公司 肿瘤坏死α因子信号的调节因子
ATE493980T1 (de) * 2002-11-21 2011-01-15 Genzyme Corp Verwendung eines diamidderivats zur verhinderung der chronischen transplantatabstossung
AU2003291143A1 (en) * 2002-11-21 2004-06-18 Genzyme Corporation Combination of diamide derivatives and immunosuppressive agents for induction of immune tolerance
WO2013142376A1 (en) * 2012-03-19 2013-09-26 Aposignal Bioscience Llc Composition and methods for cell modulation
ITMI20120814A1 (it) * 2012-05-11 2013-11-12 Diego Dolcetta Somministrazione intratecale, preferibilmente intraventricolare, di inibitori di mtor per la terapia di alcune malattie neurodegenerative, neuro-infiammatorie, neuro-oncologiche
KR102490952B1 (ko) * 2016-05-03 2023-01-19 에스큐지 바이오테크놀로지스 컴퍼니 관용을 유도하는 생체분자의 세포내 전달

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB401747A (en) * 1932-12-28 1933-11-23 Charles Hepburn Myrtle Method of and means for disinfecting air and distributing the treated air
US5672347A (en) * 1984-07-05 1997-09-30 Genentech, Inc. Tumor necrosis factor antagonists and their use
US4944796A (en) * 1988-11-14 1990-07-31 Ici Americas Inc. Certain 2-(disubstituted amino) acetanilide herbicides
US5540931A (en) * 1989-03-03 1996-07-30 Charles W. Hewitt Methods for inducing site-specific immunosuppression and compositions of site specific immunosuppressants
US4997950A (en) * 1989-04-20 1991-03-05 Richard Finbar Murphy Novel C-terminal gastrin antagonists
US5100899A (en) * 1989-06-06 1992-03-31 Roy Calne Methods of inhibiting transplant rejection in mammals using rapamycin and derivatives and prodrugs thereof
US5958413A (en) * 1990-11-01 1999-09-28 Celltech Limited Use of antibodies to TNF or fragments derived thereof and xanthine derivatives for combination therapy and compositions therefor
US6420374B1 (en) * 1990-11-30 2002-07-16 Fred Hutchinson Cancer Research Center Use of xanthines as immunosuppressants and to inhibit allograft reactions
US5861382A (en) * 1992-05-01 1999-01-19 Yeda Research And Development Co. Ltd. Methods for regulation of active TNF-α
WO1995009652A1 (en) 1993-10-06 1995-04-13 The Kennedy Institute For Rheumatology Treatment of autoimmune and inflammatory disorders
US6270766B1 (en) * 1992-10-08 2001-08-07 The Kennedy Institute Of Rheumatology Anti-TNF antibodies and methotrexate in the treatment of arthritis and crohn's disease
AU5152293A (en) 1992-10-08 1994-05-09 Kennedy Institute Of Rheumatology, The Treatment of autoimmune and inflammatory disorders
US6645493B1 (en) * 1993-05-17 2003-11-11 The Picower Institute For Medical Research Composition containing anti-MIF antibody
NZ278607A (en) * 1994-02-07 1999-05-28 Knoll Ag Use of tnf antagonists for treating disorders involving elevated serum levels of il-6 wherein the serum levels are 500pg/ml or above
DE4430128A1 (de) * 1994-08-25 1996-02-29 Hoechst Ag Kombinationspräparat mit immunsuppressiven, kardiovaskulären und cerebralen Wirkungen
DE4430127A1 (de) * 1994-08-25 1996-03-14 Hoechst Ag Kombinationspräparat, enthaltend Cyclosporin A oder FK506 und ein Xanthinderivat
JPH11501289A (ja) * 1994-12-02 1999-02-02 藤沢薬品工業株式会社 Ｎｏ介在疾患の予防および／または治療のためのペプチド化合物
US6306840B1 (en) * 1995-01-23 2001-10-23 Biogen, Inc. Cell adhesion inhibitors
FR2730411B1 (fr) * 1995-02-14 1997-03-28 Centre Nat Rech Scient Association medicamenteuse utile pour la transfection et l'expression in vivo d'exogenes
US5654312A (en) * 1995-06-07 1997-08-05 Andrulis Pharmaceuticals Treatment of inflammatory and/or autoimmune dermatoses with thalidomide alone or in combination with other agents
ATE259235T1 (de) * 1995-07-20 2004-02-15 Cell Eng Ag Zubereitung enthaltend glykane übereinstimmend mit transferrin glykaner als aktives prinzip für die induktion der immuntoleranz gegen antigene
IL115245A (en) * 1995-09-11 2002-12-01 Yissum Res Dev Co Tumor necrosis factor inhibiting pharmaceuticals
WO1997019075A1 (en) * 1995-11-22 1997-05-29 Darwin Discovery Limited Mercaptoalkylpeptidyl compounds having an imidazole substituent and their use as inhibitors of matrix metalloproteinases (mmp) and/or tumour necrosis factor (tnf)
US6090382A (en) * 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
US6211160B1 (en) * 1996-09-06 2001-04-03 The Trustees Of The University Of Pennsylvania Method for tolerizing a mammalian patient to administration of gene therapy virus vectors
JP2001513754A (ja) * 1996-12-06 2001-09-04 アムジェン インコーポレイテッド Ｔｎｆ媒介疾患を処置するためのｔｎｆ結合タンパク質を使用する組み合わせ治療
NZ337073A (en) * 1997-01-10 2001-01-26 Biogen Inc use of an anti CD40L compound to treat a patient with an autoimmune disease or chronic immune system disorder
US6294170B1 (en) * 1997-08-08 2001-09-25 Amgen Inc. Composition and method for treating inflammatory diseases
WO1998039026A2 (en) * 1997-03-07 1998-09-11 Biogen, Inc. Methods of therapeutic administration of anti-cd40l compounds
US5801193A (en) * 1997-04-15 1998-09-01 Immune Modulation, Inc. Compositions and methods for immunosuppressing
US6506569B1 (en) * 1997-05-30 2003-01-14 Human Genome Sciences, Inc. Antibodies to human tumor necrosis factor receptor TR10
US6503184B1 (en) * 1997-10-21 2003-01-07 Human Genome Sciences, Inc. Human tumor necrosis factor receptor-like proteins TR11, TR11SV1 and TR11SV2
US6407218B1 (en) * 1997-11-10 2002-06-18 Cytimmune Sciences, Inc. Method and compositions for enhancing immune response and for the production of in vitro mabs
US6359061B1 (en) * 1999-03-19 2002-03-19 Isis Pharmaceuticals, Inc. Amide compound libraries
EP1165500A1 (en) * 1999-04-02 2002-01-02 Du Pont Pharmaceuticals Company Amide derivatives as inhibitors of matrix metalloproteinases,tnf-alpha,and aggrecanase
US6204245B1 (en) * 1999-09-17 2001-03-20 The Regents Of The University Of California Treatment of narcolepsy with immunosuppressants
WO2001034649A2 (en) * 1999-11-09 2001-05-17 Chiron Corporation Compositions and methods for treating autoimmune diseases and transplant rejections
CN100494182C (zh) * 2000-05-12 2009-06-03 基酶有限公司 肿瘤坏死α因子信号的调节因子
AU2001260081B2 (en) * 2000-05-22 2005-07-28 Leo Pharma A/S Benzophenones as inhibitors of il-1beta and tnf-alpha
AU2003280429A1 (en) * 2002-06-26 2004-01-19 The Trustees Of Columbia Uninersity In The City Of New York Use of streptavidin to inhibit transplant rejection
AU2003291143A1 (en) * 2002-11-21 2004-06-18 Genzyme Corporation Combination of diamide derivatives and immunosuppressive agents for induction of immune tolerance
ATE493980T1 (de) * 2002-11-21 2011-01-15 Genzyme Corp Verwendung eines diamidderivats zur verhinderung der chronischen transplantatabstossung
EP2029729A2 (en) * 2006-05-31 2009-03-04 Genzyme Corporation Methods of using anti-thymocyte globulin and related agents

Similar Documents

Publication Publication Date Title
JP6449199B2 (ja) ヒト促進細胞およびその使用
JP3287851B2 (ja) ポルフィリンによる移植片生存の延長
AU2009251168A1 (en) Universal chimera bank
EP2521552A1 (en) Diazoxide for use in the treatment of a central nervous system (cns) autoimmune demyelinating disease
DE3812605A1 (de) Immunregulative stoffe und stoffgemische zur aktiven beeinflussung des krankheitsverlaufes
CN103270050A (zh) 用于稳定和长期移植的免疫抑制药物组合
Siemionow et al. Advances in composite tissue allograft transplantation as related to the hand and upper extremity
JP2011016851A (ja) 免疫寛容を誘導するためのジアミド誘導体と免疫抑制剤との組み合わせ
CN105358678A (zh) 治疗和/或预防1型糖尿病的方法和组合物
JP2006514015A5 (https=)
AU2002311601C1 (en) Non-myeloablative tolerogenic treatment with tyrphostins
US5013719A (en) Method of effecting immunosuppression
Starzl The French heritage in clinical kidney transplantation
KR101694554B1 (ko) 자연살해세포 억제제 및 간엽줄기세포를 유효성분으로 포함하는 이식편대숙주질환의 예방 또는 치료를 위한 세포치료제 조성물
TW202120092A (zh) 化合物用於預防或治療移植物抗宿主病的用途
NL8700191A (nl) Immunosuppressieve middelen, farmaceutische preparaten die ze bevatten en het toepassen van deze middelen.
HK1074797B (en) Combination of a diamide derivative and immunosuppressive agents for inhibiting transplant rejection
SPRANGERS et al. 20 Other Forms of
Ganschow et al. MAINTAINED EFFICIACY WITH STEROID MINIMIZATION AFTER PEDIATRIC LIVER TRANSPLANTATION WITH BASILIXIMAB (SIMULECT®) INDUCTION THERAPY: A MULTICENTER RANDOMIZED 12-MONTH TRIAL.: 78
JPH04327541A (ja) 拒絶反応による移植臓器障害治療剤
Shah et al. INDUCTION IMMUNOSUPPRESSION WITH RABBIT ANTITHYMOCYTE GLOBULIN IN PEDIATRIC LIVER TRANSPLANTATION.: 80
Kelly et al. HEMODYNAMIC CHANGES FOLLOWING TRANSPLANTATION OF MARGINAL SIZE PIG LIVER GRAFTS.: 77